Harpoon Therapeutics, Inc.

NasdaqCM:HARP Stock Report

Market Cap: US$492.3m

Harpoon Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqCM:HARP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Mar 24SellUS$31,629,758GAMCO Investors, Inc.Company1,375,331US$23.00
12 Mar 24SellUS$9,016,000Gabelli & Company Investment Advisers, Inc.Company392,000US$23.00
06 Mar 24BuyUS$6,731,487GAMCO Investors, Inc.Company293,200US$22.98
26 Feb 24BuyUS$0GAMCO Investors, Inc.Company1,087,281US$22.95
22 Feb 24BuyUS$0Gabelli & Company Investment Advisers, Inc.Company396,850US$22.94
21 Feb 24SellUS$116,495GAMCO Investors, Inc.Company5,150US$22.62
21 Feb 24SellUS$109,709Gabelli & Company Investment Advisers, Inc.Company4,850US$22.62

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of HARP?
Owner TypeNumber of SharesOwnership Percentage
Private Companies00%
Individual Insiders57,7900.27%
General Public1,300,9746.08%
Public Companies2,399,82411.2%
Hedge Funds3,849,06018%
VC/PE Firms4,659,16921.8%
Institutions9,130,38842.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 543.9%.


Top Shareholders

Top 25 shareholders own 92.24% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.2%
Merck & Co., Inc.
2,399,824US$55.2m0%no data
11%
Cormorant Asset Management, LP
2,349,060US$54.1m4,250%2.27%
8.69%
New Leaf Venture Partners, LLC
1,859,169US$42.8m0%26.26%
7.01%
RA Capital Management, L.P.
1,500,000US$34.5m0%0.45%
7.01%
Commodore Capital LP
1,500,000US$34.5m0%2.21%
6.97%
Franklin Resources, Inc.
1,492,368US$34.3m1,030%0.01%
6.08%
Artal Group S.A.
1,300,000US$29.9m-31.7%0.81%
5.06%
GAMCO Investors, Inc.
1,082,131US$24.9m0%0.1%
4.11%
The Vanguard Group, Inc.
880,017US$20.2m676%no data
3.84%
Soleus Capital Management, L.P.
820,638US$18.9m0%1.77%
3.81%
Blackstone Alternative Asset Management L.P.
815,000US$18.8m0%10.38%
3.2%
Citadel Advisors LLC
685,000US$15.8m1,300%0.02%
2%
Ally Bridge Group
428,400US$9.9m0%2.85%
1.83%
Gabelli & Company Investment Advisers, Inc.
392,000US$9.0m0%1.87%
1.49%
BioImpact Capital LLC
319,670US$7.4m0%1.3%
1.46%
MPM Asset Management, L.L.C.
313,136US$7.2m0%2.57%
1.4%
Adage Capital Management, L.P.
300,000US$6.9m0%0.01%
1.39%
Sio Capital Management, LLC
297,936US$6.9m77.3%2.48%
1.17%
BlackRock, Inc.
249,834US$5.7m576%no data
1.07%
Lion Point Capital, LP
228,900US$5.3m178%4.42%
1.02%
Arix Bioscience plc
219,093US$5.0m0%27.04%
0.7%
Geode Capital Management, LLC
149,262US$3.4m499%no data
0.25%
Water Island Capital, LLC
54,472US$1.3m0%0.14%
0.24%
Kennedy Capital Management LLC
52,160US$1.2m-1.56%0.03%
0.23%
Goldman Sachs Group, Investment Banking and Securities Investments
48,948US$1.1m0%no data
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.